TB-500 vs Actovegin: Comparing Two Different Approaches to Recovery Research

Q: Is Actovegin banned by WADA?

Not outright. WADA's own analysis found Actovegin does not contain prohibited hormones or oxygen-transport-enhancing blood products, so it is not on the Prohibited List. However, WADA's M2 rule restricts intravenous infusion volume to no more than 100 mL and requires serial IV doses to be spaced at least 12 hours apart, which applies to Actovegin administration in practice.

> Research disclaimer: This article compares publicly available research and regulatory information on thymosin beta-4 (TB-500) and Actovegin, for informational purposes only. Neither compound is FDA-approved for human therapeutic use in the United States. Nothing here is medical advice, a dosing recommendation, or a protocol suggestion.

What Each Compound Actually Is

| | TB-500 | Actovegin |
|---|---|---|
| Source | Synthetic fragment of thymosin beta-4, a naturally occurring protein | Deproteinized extract (hemodialysate/ultrafiltrate) derived from the blood of young calves |
| Composition | A single, defined peptide sequence | A complex mixture: oligopeptides, nucleotides, amino acids, glycolipids, and trace elements |
| Regulatory status (US) | Sold as an unapproved research chemical, not FDA-approved | Not FDA-approved; not legally marketed as a pharmaceutical in the United States |
| Regulatory status (elsewhere) | Similar research-chemical framing in most countries | Manufactured in Austria and approved as a pharmaceutical product in a number of countries in Europe and elsewhere |
| WADA status | On the Prohibited List at all times, as a peptide hormone/growth factor category substance | Not on the Prohibited List itself, but subject to WADA's M2 rule restricting intravenous infusion volume and frequency |
| Primary research context | Cytoskeletal cell migration, tissue repair, angiogenesis | Oxidative metabolism, wound healing, and sports-recovery applications, mostly outside the US |

The table format is a useful starting point here because these two compounds are genuinely different kinds of substances, not two variations on the same research question. TB-500 is a single, chemically defined molecule. Actovegin is an extract — a mixture of many biologically active fragments — which changes both how it's studied and how its regulatory status has to be evaluated.

What Actovegin Actually Is

Actovegin is manufactured by deproteinizing (removing the proteins from) blood drawn from young calves, leaving behind a filtrate composed of oligosaccharides, nucleotides, low-molecular-weight polypeptides, glycolipids, amino acids, metabolic intermediates of sugars and lipids, and trace elements. It has been used in European sports medicine and general clinical practice for decades, primarily for wound healing, peripheral circulatory disorders, and — the application most relevant to this comparison — as a recovery aid in sports medicine, typically administered by injection or infusion.

Actovegin became widely known outside clinical circles because of its association with high-profile athletes and doping controversies, particularly around the Sydney Olympics and the 2000 Tour de France, where its use by elite cyclists drew scrutiny even though the World Anti-Doping Agency's own analysis found it does not contain prohibited hormones or blood cells capable of increasing oxygen transport. That analysis is the reason Actovegin itself has not been added to WADA's Prohibited List, even as it remains associated with doping-adjacent controversy in sports media.

Mechanism: A Defined Peptide vs. a Metabolic Mixture

TB-500's proposed mechanism is comparatively well characterized for a research peptide: it works primarily through actin sequestration, binding G-actin and influencing cytoskeletal reorganization that drives cell migration toward damaged tissue. That mechanism is covered in depth in our TB-500 mechanism of action guide, and it underlies the tendon, muscle, and wound-healing research discussed throughout this site.

Actovegin's proposed mechanism is different in kind, not just in specifics, because it isn't a single active ingredient. Research on Actovegin has focused substantially on mitochondrial oxidative metabolism — laboratory work has shown Actovegin increasing oxidative phosphorylation capacity in the presence of Complex I-linked substrates in a concentration-dependent manner, suggesting an effect on cellular energy production rather than the cytoskeletal cell-migration pathway TB-500 works through. Because Actovegin is a complex biological extract rather than a single defined molecule, isolating which specific component (or combination of components) drives any observed effect is a harder research problem than it is for a single-sequence peptide like TB-500.

The Evidence Base: Neither Is Strongly Established, But Differently

Systematic reviews of Actovegin's use in sports medicine have generally found limited evidence supporting a meaningful performance or recovery benefit from intramuscular injection, despite decades of clinical use in the countries where it's approved. That's a notably similar conclusion to where TB-500's evidence base currently sits — real preclinical and mechanistic research exists, but well-controlled human trials demonstrating a clear recovery benefit are thin for both compounds, just for different underlying reasons. TB-500's gap is largely that it hasn't gone through formal human drug trials under its own name (see our human clinical trials overview). Actovegin's gap is that despite extensive clinical use and some mechanistic laboratory data, controlled trials specifically evaluating sports-recovery outcomes have not consistently demonstrated a clear effect over placebo.

Neither compound's research gap should be read as a claim that the substance "doesn't work" — the more accurate framing is that neither has cleared the evidentiary bar that would normally be required for an approved recovery therapeutic, for reasons specific to each compound's development and regulatory path.

Regulatory Status Compared in Detail

The regulatory comparison here is genuinely more nuanced than most TB-500 comparison content suggests:

TB-500 is banned for competitive athletes under WADA's Prohibited List at all times, in and out of competition, as covered in our TB-500 legal status overview. It is not a controlled substance and is sold in the US as a research chemical, not for human consumption.

Actovegin is not on WADA's Prohibited List, since WADA's own review found it doesn't contain banned hormones or oxygen-transport-enhancing blood products. However, it isn't unregulated for athletes either — WADA's M2 rule (Chemical and Physical Manipulation) prohibits intravenous infusions or injections exceeding 100 mL, and requires that serial IV administrations be spaced at least 12 hours apart, regardless of the substance being infused. Actovegin's doping-adjacent reputation comes largely from this infusion-method restriction and its high-profile use by elite athletes, not from the substance itself being prohibited.

In the United States specifically, Actovegin is not FDA-approved and isn't legally marketed as a pharmaceutical product, even though it's an approved medicine in Austria (where it's manufactured) and a number of other countries. That puts it in a different position than TB-500: Actovegin has actual pharmaceutical approval status, just not in the US, whereas TB-500 has never achieved pharmaceutical approval anywhere as a standalone product.

Why the Comparison Gets Muddled in Recovery Communities

Both compounds get discussed in the same "athlete recovery" conversations, which creates an impression of interchangeability that their actual profiles don't support. TB-500 is a single synthetic peptide sold through research-chemical channels, banned outright for tested athletes, with a mechanistic research base built around cell migration and tissue repair. Actovegin is an approved pharmaceutical product in several countries (not the US), permitted for athletes subject to WADA testing as long as infusion-volume rules are followed, with a research base built around metabolic and circulatory effects. Lumping them together as equivalent "recovery peptides" obscures both their different regulatory realities and their different biological mechanisms.

What's Still Unknown

No published study has directly compared TB-500 and Actovegin head-to-head in the same recovery model.

The specific active component(s) within Actovegin's complex mixture responsible for its studied oxidative-metabolism effects haven't been fully isolated and independently confirmed.

Whether Actovegin's clinical use pattern in countries where it's approved translates to any benefit relevant to the tissue-repair questions TB-500 research addresses has not been established — the two compounds' research literatures don't meaningfully overlap.

Frequently Asked Questions

Is Actovegin the same kind of substance as TB-500?
No. TB-500 is a single synthetic peptide fragment of thymosin beta-4. Actovegin is a deproteinized extract derived from calf blood, containing a complex mixture of oligopeptides, nucleotides, amino acids, and other components — not a single defined molecule.

Is Actovegin banned by WADA?
Not outright. WADA's own analysis found Actovegin doesn't contain prohibited hormones or oxygen-transport-enhancing blood products, so it isn't on the Prohibited List. However, WADA's M2 rule restricts intravenous infusion volume (no more than 100 mL) and requires serial IV doses to be spaced at least 12 hours apart, which applies to Actovegin administration in practice.

Is Actovegin legal in the United States?
It is not FDA-approved and is not legally marketed as a pharmaceutical product in the United States, even though it's an approved medicine in Austria, where it's manufactured, and in a number of other countries.

Does Actovegin work through the same mechanism as TB-500?
No. TB-500's proposed mechanism centers on actin regulation and cytoskeletal cell migration. Actovegin's studied effects relate more to mitochondrial oxidative metabolism and circulatory function — a different biological pathway entirely.

Which has stronger evidence for recovery benefits, TB-500 or Actovegin?
Neither has a strong, well-controlled human evidence base specific to recovery outcomes. Actovegin has decades of clinical use in countries where it's approved, but systematic reviews have found limited evidence for a clear sports-recovery benefit. TB-500's evidence base is largely preclinical and hasn't gone through comparable human clinical trials under its own name.

Sourcing Quality TB-500 for Research

Comparing research compounds only matters if the material actually being studied is verifiably what the label claims. Apollo Peptide Sciences publishes third-party HPLC testing and certificates of analysis for its TB-500. See our peptide buying guide for what to verify before sourcing any research compound.

---